Phoenix

Nanopharmaceuticals represent a rapidly advancing frontier in modern medicine, offering novel therapeutic solutions by leveraging the unique behaviors of materials at the nanoscale. Unlike conventional drugs, nanoformulations harness the distinct physical, chemical, and biological properties that emerge when particle sizes are reduced to the nanometer range. These differences—especially in terms of pharmacokinetics, biodistribution, and efficacy—require an equally specialized approach for development, characterization, and manufacturing.

However, translating these promising innovations from the research bench to clinical and commercial application remains a significant challenge for biotech and pharmaceutical companies, especially start-ups and SMEs. Scaling up nanoformulations, ensuring consistent quality, navigating GMP production, and meeting regulatory expectations demand not only scientific excellence but also access to the right infrastructure and expertise.

PHOENIX-OITB (Open Innovation Test Bed) was established to bridge this gap—offering an integrated, end-to-end ecosystem that accelerates the development and industrialization of nanopharmaceuticals. Through its Single Entry Point (SEP), PHOENIX enables seamless access to a consolidated network of facilities, technologies, and expert services. From early-stage R&D to GMP manufacturing and innovation and regulatory support, PHOENIX is designed to streamline every stage of the product journey—saving time, reducing risk, and ensuring quality.

Within this project, MyB, BNN and CSIC along with all service providers co-developed the PHOENIX-OITB Service Portfolio, reflecting the evolving capabilities of our network. It includes: